- Home
- SCLX vs NTIP Comparison
SCLX vs NTIP Comparison
Compare SCLX & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- NTIP
- Stock Information
- Founded
- SCLX 2011
- NTIP 1990
- Country
- SCLX United States
- NTIP United States
- Employees
- SCLX N/A
- NTIP N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- SCLX Health Care
- NTIP Miscellaneous
- Exchange
- SCLX Nasdaq
- NTIP Nasdaq
- Market Cap
- SCLX 35.7M
- NTIP 32.0M
- IPO Year
- SCLX N/A
- NTIP 1998
- Fundamental
- Price
- SCLX $24.96
- NTIP $1.58
- Analyst Decision
- SCLX Strong Buy
- NTIP
- Analyst Count
- SCLX 3
- NTIP 0
- Target Price
- SCLX $367.50
- NTIP N/A
- AVG Volume (30 Days)
- SCLX 205.7K
- NTIP 65.6K
- Earning Date
- SCLX 08-13-2025
- NTIP 10-23-2025
- Dividend Yield
- SCLX N/A
- NTIP 6.25%
- EPS Growth
- SCLX N/A
- NTIP N/A
- EPS
- SCLX N/A
- NTIP N/A
- Revenue
- SCLX $44,236,000.00
- NTIP $150,000.00
- Revenue This Year
- SCLX $89.26
- NTIP N/A
- Revenue Next Year
- SCLX $203.95
- NTIP N/A
- P/E Ratio
- SCLX N/A
- NTIP N/A
- Revenue Growth
- SCLX N/A
- NTIP N/A
- 52 Week Low
- SCLX $3.60
- NTIP $1.16
- 52 Week High
- SCLX $39.90
- NTIP $1.90
- Technical
- Relative Strength Index (RSI)
- SCLX 64.44
- NTIP 54.20
- Support Level
- SCLX $22.45
- NTIP $1.56
- Resistance Level
- SCLX $27.58
- NTIP $1.63
- Average True Range (ATR)
- SCLX 2.32
- NTIP 0.08
- MACD
- SCLX 0.09
- NTIP -0.01
- Stochastic Oscillator
- SCLX 74.71
- NTIP 27.27
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.